DiaMedica Therapeutics' (DMAC) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell" rating for DiaMedica Therapeutics (DMAC), indicating a negative outlook on the stock.
• Despite the sell rating from Weiss, other analysts like Lake Street Capital and HC Wainwright have given DMAC a "buy" rating, with price targets ranging from $11 to $14.
• Insider trading activity saw major shareholder Jan Stahlberg purchasing over 50,000 shares, increasing their ownership stake in the company significantly.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Several other equities research analysts also recently weighed in on the company. Lake Street Capital increased their price objective on DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a report on Friday, July 18th. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Craig Hallum increased their price target on DiaMedica Therapeutics from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Friday, July 18th. Finally, Wall Street Zen raised DiaMedica Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, October 4th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock traded up $0.12 during trading hours on Friday, hitting $6.88. The stock had a trading volume of 309,492 shares, compared to its average volume of 244,700. The firm has a market capitalization of $355.63 million, a PE ratio of -9.97 and a beta of 1.40. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $7.49. The stock's 50 day moving average is $6.58 and its 200 day moving average is $4.95.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). As a group, equities analysts predict that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Insider Buying and Selling at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg purchased 50,772 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average cost of $6.00 per share, with a total value of $304,632.00. Following the completion of the acquisition, the insider directly owned 7,764,465 shares in the company, valued at $46,586,790. This trade represents a 0.66% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired 1,000,000 shares of company stock worth $5,958,598 over the last three months. 7.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DMAC. World Investment Advisors lifted its holdings in DiaMedica Therapeutics by 17.0% in the first quarter. World Investment Advisors now owns 25,650 shares of the company's stock valued at $97,000 after acquiring an additional 3,735 shares during the period. Royal Bank of Canada lifted its holdings in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after acquiring an additional 154,701 shares during the period. Goldman Sachs Group Inc. lifted its holdings in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company's stock valued at $462,000 after acquiring an additional 52,854 shares during the period. Jane Street Group LLC lifted its holdings in DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock valued at $382,000 after acquiring an additional 58,457 shares during the period. Finally, Perigon Wealth Management LLC acquired a new stake in DiaMedica Therapeutics in the second quarter valued at $207,000. Institutional investors and hedge funds own 10.12% of the company's stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.